<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FLOT1 Protein (Flotillin-1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>FLOT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>FLOT1 (Flotillin-1)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=FLOT1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">cancer</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">glioblastoma</a>, <a href="/wiki/major-depressive-disorder" style="color:#ef9a9a">major depressive disorder</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-a015e80e" style="color:#ce93d8" title="Score: 0.42">Flotillin-1 Stabilization Compounds...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FLOT1 Protein (Flotillin-1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>FLOT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>FLOT1 (Flotillin-1)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=FLOT1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">cancer</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">glioblastoma</a>, <a href="/wiki/major-depressive-disorder" style="color:#ef9a9a">major depressive disorder</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-a015e80e" style="color:#ce93d8" title="Score: 0.42">Flotillin-1 Stabilization Compounds...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>
Flotillin-1 (FLOT1) is a 427-amino acid integral membrane protein belonging to the flotillin family (also known as reggaes). This protein serves as a crucial marker and organizer of lipid rafts—dynamic, cholesterol-rich membrane microdomains that concentrate signaling molecules and facilitate coordinated cellular responses. Flotillin-1 is expressed ubiquitously with particularly high levels in the brain, where it plays essential roles in neuronal signaling, synaptic function, and membrane organization[@flottilin2011].
In the central nervous system, flotillin-1 is enriched in neurons and glia, where it localizes to lipid rafts that serve as platforms for amyloid precursor protein (APP) processing, neurotransmitter receptor signaling, and synaptic vesicle organization. The protein forms hetero-oligomeric complexes with flotillin-2 (FLOT2), creating stable microdomain structures that are essential for maintaining neuronal membrane integrity and function. Alterations in flotillin-1 expression and lipid raft organization have been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@lipid2020].
Flotillin-1 is a 47 kDa integral membrane protein characterized by several distinctive structural features that enable its function in lipid raft organization. The protein contains an N-terminal hydrophobic region (amino acids 1-20) that mediates membrane association, followed by the SPFH domain (Stomatin/Prohibitin/Flotillin/HflC/K, amino acids 21-180), which is involved in protein-protein interactions and oligomerization. The C-terminal region (amino acids 250-400) contains coiled-coil motifs that facilitate protein-protein interactions and higher-order complex formation[@flottilin2011].
The SPFH domain is conserved across the flotillin family and serves as a scaffolding platform that recruits other proteins to lipid rafts. This domain interacts with various signaling molecules, cytoskeletal proteins, and membrane receptors, enabling flotillin-1 to coordinate multiple cellular processes. The oligomeric nature of flotillin-1 (forming homo- and hetero-oligomers with flotillin-2) is essential for its function in creating stable membrane microdomains. These oligomers can form large complexes of 10-20 subunits that create specialized membrane domains.
Flotillin-1 undergoes post-translational modifications including phosphorylation and palmitoylation, which regulate its membrane association, oligomerization, and protein-protein interactions. Phosphorylation on tyrosine residues has been implicated in signaling cascades, while palmitoylation enhances its affinity for cholesterol-rich membrane regions. The protein is relatively stable with a half-life of 24-48 hours in most cell types, though its turnover may be regulated under specific physiological and pathological conditions.
In the healthy brain, flotillin-1 fulfills several critical functions that maintain neuronal health and signaling capacity. The protein's primary role is as a structural organizer of lipid rafts, where it creates stable platforms that concentrate specific sets of signaling molecules, receptors, and adhesion proteins. These microdomains are essential for efficient signal transduction, as they enable high local concentrations of interacting proteins while maintaining spatial specificity.
Flotillin-1 plays a crucial role in synaptic organization and function. The protein is enriched at synapses, where it associates with both presynaptic and postsynaptic compartments. At the presynaptic terminal, flotillin-1 organizes lipid rafts that contain synaptic vesicle proteins, including synaptophysin and synaptotagmin, facilitating efficient vesicle cycling and neurotransmitter release. Postsynaptically, flotillin-1 clusters with glutamate receptors, including NMDA and AMPA receptors, modulating receptor trafficking and signaling[@schneider2017].
The protein also participates in neuronal signal transduction by serving as a platform for various kinase and phosphatase pathways. Flotillin-1 interacts with members of the Src family kinases, including Fyn and Lck, which are involved in regulating synaptic plasticity and receptor function. Additionally, flotillin-1 associates with insulin receptors and EGFR family receptors, linking metabolic signaling to neuronal function. The protein's ability to organize multiple signaling pathways makes it a central regulator of neuronal homeostasis.
Flotillin-1 is involved in endocytosis and membrane trafficking processes that are essential for neuronal function. The protein regulates both clathrin-dependent and clathrin-independent endocytic pathways, particularly those involving lipid raft-mediated uptake. This function is important for synaptic vesicle recycling, receptor internalization, and the clearance of membrane-associated proteins. The protein also participates in the trafficking of amyloid precursor protein and its processing enzymes.
Alzheimer's disease (AD) involves extensive alterations in lipid raft organization and function, with flotillin-1 playing a central role in these changes. Flotillin-1 is highly enriched in lipid rafts where amyloid precursor protein (APP) and the amyloid-beta (Aβ) generating enzymes (β-secretase and γ-secretase) are concentrated. This spatial proximity facilitates amyloidogenic APP processing and Aβ generation, making lipid rafts and flotillin-1 key elements in the amyloid cascade hypothesis[@kim2018].
Studies have demonstrated that flotillin-1 expression is altered in AD brain tissue. Both flotillin-1 and flotillin-2 show increased expression in certain brain regions affected by AD, particularly in areas with high amyloid plaque burden. This upregulation may represent a compensatory response to increased Aβ production or a reflection of altered membrane dynamics in affected neurons. Importantly, the interaction between flotillin-1 and Aβ extends to cellular uptake mechanisms—flotillin-1 colocalizes with internalized Aβ in neurons, indicating that lipid rafts facilitate Aβ internalization and subsequent toxicity[@letoha2019].
Flotillin-1 also influences tau pathology through mechanisms that involve lipid raft-mediated signaling. The protein modulates the activity of kinases and phosphatases that regulate tau phosphorylation, including GSK-3β and PP2A. Alterations in flotillin-1 expression may therefore contribute to the hyperphosphorylation and aggregation of tau that characterizes neurofibrillary tangles in AD. Additionally, flotillin-1's role in membrane trafficking affects the clearance of pathological tau species.
Genetic studies have identified variants in FLOT1 and FLOT2 genes that may influence AD risk, though the evidence remains preliminary. Some studies suggest that polymorphisms in lipid raft-associated genes modify the age of onset and disease progression. The protein's central position in APP processing and Aβ metabolism makes it a potential therapeutic target, though strategies to modulate flotillin-1 function must consider its essential roles in normal neuronal function.
Parkinson's disease (PD) involves alterations in membrane lipid composition and lipid raft function that affect dopaminergic neuron survival. Flotillin-1 and flotillin-2 are implicated in α-synuclein aggregation and toxicity, two central features of PD pathogenesis. The flotillin proteins interact with both monomeric and oligomeric α-synuclein, potentially facilitating the formation and spread of Lewy bodies[@morrow2020].
In PD models, flotillin-1 expression is altered in dopaminergic neurons, with changes observed in both the substantia nigra and associated brain regions. The protein's role in endocytic pathways may influence the uptake and propagation of pathological α-synuclein species between neurons. Flotillin-1 also affects mitochondrial function and oxidative stress responses, which are critical determinants of dopaminergic neuron vulnerability in PD.
Flotillin-1's involvement in lipid metabolism has implications for PD pathogenesis, as alterations in membrane lipid composition may affect neuronal resilience to various stressors. The protein's interaction with cholesterol-rich membrane domains is particularly relevant given the role of cholesterol in α-synuclein aggregation and toxicity. Strategies to modulate lipid raft composition through flotillin-1 targeting may therefore have therapeutic potential in PD.
Beyond AD and PD, flotillin-1 is implicated in several other neurodegenerative conditions. In Huntington's disease, altered flotillin-1 expression affects membrane organization and signaling in striatal neurons, potentially contributing to the selective vulnerability of these cells. The protein's role in trafficking and signaling may be particularly important in the context of mutant huntingtin-induced dysfunction.
In amyotrophic lateral sclerosis (ALS), flotillin-1 is detected in stress granules and RNA granules that accumulate in affected motor neurons. These aggregates are characteristic of ALS pathogenesis and involve RNA-binding proteins including TDP-43. Flotillin-1's presence in these structures suggests that lipid raft organization and stress response pathways intersect in ALS pathogenesis.
Flotillin-1 alterations have also been reported in frontotemporal dementia, multiple sclerosis, and certain lysosomal storage disorders. The protein's fundamental role in membrane organization means that its dysregulation affects multiple cellular processes, potentially contributing to diverse pathological outcomes.
Multiple therapeutic strategies targeting flotillin-1 and lipid raft function are being explored for neurodegenerative diseases. Lipid raft modulators that alter flotillin-1 localization or function represent one approach to modifying amyloid and α-synuclein pathology. These compounds aim to disrupt the membrane microenvironments that facilitate pathological protein aggregation while sparing normal lipid raft function.
Small molecules targeting flotillin-1 interactions are under development, with the goal of preventing deleterious protein-protein interactions without completely disrupting lipid raft organization. Peptide-based approaches that block specific flotillin-1 binding interfaces have shown promise in preclinical models. Gene therapy approaches to modulate flotillin-1 expression are also being explored, though delivery to the central nervous system remains challenging.
Another therapeutic avenue involves enhancing lipid raft function to promote neuronal resilience. This approach recognizes that flotillin-1 and lipid rafts have essential neuroprotective functions that may be harnessed to counteract neurodegeneration. Strategies to increase flotillin-1 expression or improve lipid raft integrity may therefore have beneficial effects in multiple neurodegenerative conditions.
Despite progress in understanding flotillin-1 biology in neurodegeneration, several key questions remain. The precise mechanisms by which flotillin-1 promotes or inhibits protein aggregation require further investigation. The protein's dual role in both facilitating pathological processes and maintaining normal neuronal function creates therapeutic challenges that require careful targeting strategies.
The development of flotillin-1-targeted therapeutics must address delivery challenges specific to the central nervous system. Strategies including viral vectors, nanoparticle delivery, and blood-brain barrier penetration require optimization for clinical translation. Biomarker development to identify patients who might benefit from flotillin-1-targeted interventions is another important research direction.